NASDAQ:BLPH Bellerophon Therapeutics (BLPH) Stock Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free BLPH Stock Alerts $0.06 +0.01 (+20.58%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$0.06▼$0.0650-Day Range$0.05▼$0.0652-Week Range$0.03▼$11.15Volume5,012 shsAverage Volume61,469 shsMarket Capitalization$716,678.00P/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaSustainability Get Bellerophon Therapeutics alerts: Email Address Bellerophon Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside3,313.0% Upside$2.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.86Upright™ Environmental ScoreNews Sentiment0.69Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.11 out of 5 stars 3.0 Analyst's Opinion Consensus RatingBellerophon Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageBellerophon Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for BLPH. Previous Next 0.0 Dividend Strength Dividend YieldBellerophon Therapeutics does not currently pay a dividend.Dividend GrowthBellerophon Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBellerophon Therapeutics has received a 77.00% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for pulmonary hearth diseases" and "Clinical research services for hypertension" products. See details.Environmental SustainabilityThe Environmental Impact score for Bellerophon Therapeutics is -0.86. Previous Next 3.2 News and Social Media Coverage News SentimentBellerophon Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bellerophon Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Bellerophon Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bellerophon Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of Bellerophon Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 10.61% of the stock of Bellerophon Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Bellerophon Therapeutics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bellerophon Therapeutics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBellerophon Therapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Bellerophon Therapeutics Stock (NASDAQ:BLPH)Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Read More BLPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLPH Stock News HeadlinesApril 22, 2024 | americanbankingnews.comBellerophon Therapeutics (NASDAQ:BLPH) Receives New Coverage from Analysts at StockNews.comApril 14, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)April 24, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…February 25, 2024 | uk.finance.yahoo.comBellerophon Therapeutics, Inc. (BLPH)February 15, 2024 | investing.comBellerophon Therapeutics Inc (BLPH)January 31, 2024 | msn.comBellerophon Offers Series A Stock in Private SaleNovember 28, 2023 | benzinga.comHilco Streambank Seeks Offers to Acquire Patent Portfolio and Material Inventory of Biotherapeutics Company BellerophonNovember 2, 2023 | morningstar.comBellerophon Therapeutics Inc BLPHApril 24, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…August 8, 2023 | finance.yahoo.comBLPH - Bellerophon Therapeutics, Inc.July 25, 2023 | msn.comWhat's Happening With Bellerophon Therapeutics Stock Today?July 25, 2023 | investorplace.comWhy Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today?July 6, 2023 | msn.comBellerophon Therapeutics (BLPH) Price Target Decreased by 92.23% to 2.04June 6, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Bellerophon TherapeuticsJune 6, 2023 | finance.yahoo.comIs Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?June 6, 2023 | msn.comLaidlaw & Co. Downgrades Bellerophon Therapeutics (BLPH)June 6, 2023 | msn.comHC Wainwright & Co. Maintains Bellerophon Therapeutics (BLPH) Buy RecommendationJune 5, 2023 | msn.comBellerophon Therapeutics Stock Nosedive: Here's WhyJune 5, 2023 | msn.comWhy Is Bellerophon Therapeutics (BLPH) Stock Down 79% Today?June 5, 2023 | finance.yahoo.comBellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung DiseaseMay 19, 2023 | msn.comLucy Scientific, Bioventus top healthcare gainers; Enveric, Elevation among losersMay 17, 2023 | finance.yahoo.comBellerophon Therapeutics (NASDAQ:BLPH) delivers shareholders fantastic 978% return over 1 year, surging 18% in the last week aloneMay 16, 2023 | finanznachrichten.deBellerophon Therapeutics, Inc.: Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial ResultsMay 15, 2023 | finance.yahoo.comBellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comBellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseaseApril 28, 2023 | finance.yahoo.comBellerophon Therapeutics (BLPH) Outpaces Stock Market Gains: What You Should KnowApril 24, 2023 | finance.yahoo.comBellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?See More Headlines Receive BLPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2023Today4/23/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BLPH CUSIPN/A CIK1600132 Webwww.bellerophon.com Phone(908) 574-4770FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+3,313.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,830,000.00 Net MarginsN/A Pretax Margin-186.70% Return on Equity-187.35% Return on Assets-104.97% Debt Debt-to-Equity RatioN/A Current Ratio3.96 Quick Ratio3.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book0.22Miscellaneous Outstanding Shares12,230,000Free Float11,597,000Market Cap$716,678.00 OptionableNo Data Beta0.67 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Craig R. Jalbert CIRA (Age 62)President, Treasurer, Secretary, Principal Executive, Financial & Accounting Officer and Director Key CompetitorsEvelo BiosciencesNASDAQ:EVLOEvofem BiosciencesNASDAQ:EVFMSciSparcNASDAQ:SPRCAditxtNASDAQ:ADTXChina SXT PharmaceuticalsNASDAQ:SXTCView All CompetitorsInsidersPuissance Capital Management LSold 1,076,841 sharesTotal: $107,684.10 ($0.10/share)Life Science Opportu PuissanceSold 134,421 sharesTotal: $111,569.43 ($0.83/share)Life Science Opportu PuissanceSold 560,000 sharesTotal: $5.30 M ($9.46/share)Bobae KimSold 9,455 sharesTotal: $94,550.00 ($10.00/share)View All Insider Transactions BLPH Stock Analysis - Frequently Asked Questions Should I buy or sell Bellerophon Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BLPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLPH, but not buy additional shares or sell existing shares. View BLPH analyst ratings or view top-rated stocks. What is Bellerophon Therapeutics' stock price target for 2024? 2 Wall Street research analysts have issued 1-year target prices for Bellerophon Therapeutics' stock. Their BLPH share price targets range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 3,313.0% from the stock's current price. View analysts price targets for BLPH or view top-rated stocks among Wall Street analysts. How have BLPH shares performed in 2024? Bellerophon Therapeutics' stock was trading at $0.0370 on January 1st, 2024. Since then, BLPH shares have increased by 58.4% and is now trading at $0.0586. View the best growth stocks for 2024 here. When is Bellerophon Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our BLPH earnings forecast. How were Bellerophon Therapeutics' earnings last quarter? Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) announced its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.42) EPS for the quarter. When did Bellerophon Therapeutics' stock split? Bellerophon Therapeutics's stock reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Bellerophon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX). When did Bellerophon Therapeutics IPO? Bellerophon Therapeutics (BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers. How do I buy shares of Bellerophon Therapeutics? Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLPH) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellerophon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
